Sankyo

Business

AstraZeneca, Daiichi Sankyo ADC misses key endpoint in phase 3 lung cancer trial

Love Employee/iStock via Getty Images Datopotamab deruxtecan, an antibody drug conjugate under development from AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF),…

Read More »
Back to top button